ESPN Releases Score Prediction For Michigan-Florida

first_imgHead coach Jim Harbaugh of the Michigan Wolverines reacts during the college football game against the Michigan State Spartans at Michigan Stadium.ANN ARBOR, MI – OCTOBER 17: Head coach Jim Harbaugh of the Michigan Wolverines reacts during the college football game against the Michigan State Spartans at Michigan Stadium on October 17, 2015 in Ann Arbor, Michigan. The Spartans defeated the Wolverines 27-23. (Photo by Christian Petersen/Getty Images)The Michigan-Florida matchup in the Chick-fil-A Peach Bowl is among the most intriguing bowl matchups of the season.The Wolverines are looking to avenge their blowout loss to Ohio State that knocked them out of the Big Ten title race and College Football Playoff.The Gators are hoping to make up for missed opportunities in the SEC throughout the season and end the season on a high-note.It will be an exciting Big Ten-SEC matchup, and predictions for the game are starting to trickle in.According to ESPN Staff Writer Adam Rittenberg, the Michigan Wolverines will beat the Florida Gators by a score of 31-21.The two teams have played against each other only four times – twice with Harbaugh at the helm for Michigan, and three of which were bowl games.The Wolverines have emerged victorious in each of the four meetings.Michigan and Florida last played against each other in the 2017 regular season, with the Wolverines winning 33-17.last_img read more

Valeant to sell iNova Pharmaceuticals for US930 million cash to 2 fund

LAVAL, Que. – Valeant Pharmaceuticals (TSX:VRX) expects to receive US$930 million in cash for its iNova unit, which it’s selling to two fund managers that had been considered rival bidders for the prescription and over-the-counter drug business.The buyers are funds managed by Pacific Equity Partners and The Carlyle Group, which say they plan to further grow Nova Pharmaceuticals.iNova markets a variety of products for weight management, pain management, cardiology and the treatment of coughs and colds.“We are very pleased to have finalized an agreement to acquire iNova. This is a strong company with great products with growth opportunities particularly in new markets,” Carlyle Group managing director David Bluff said in a statement.David Brown, managing director of Pacific Equity Partners, said the new owners intend to invest in product development, geographical expansion, marketing, staff and potential acquisitions of additional brands.“We are now working with Valeant and the relevant regulatory authorities to close the transaction in the second half of 2017,” Brown said in the joint statement with Carlyle Group.Valeant, based in Laval, Que., says in its separate statement that it will use proceeds from the sale of iNova to repay debt.“The sale of iNova is part of the company’s ongoing efforts to both simplify our operating model and strengthen our balance sheet,” said Joseph Papa, Valeant’s chairman and chief executive officer.“We will continue to evaluate opportunities that will enable us to deliver on our commitments and unlock value for shareholders.”None of the companies announced how the iNova deal will be split between the two buyers.Analyst Douglas Miehm of RBC Dominion Securities wrote in a note to clients that the transaction appears to be positive for Valeant and suggests that further deals will follow as it works to cut US$5 billion of debt by next February.Valeant shares were up slightly in extended trading before North American stock markets opened Thursday. Valeant to sell iNova Pharmaceuticals for US$930 million cash to 2 fund managers by The Canadian Press Posted Jun 8, 2017 5:27 am MDT Last Updated Jun 8, 2017 at 6:20 am MDT AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email read more